Caremo Announces Successful Completion of RMB 150 Million Series A Financing!

On June 18, 2022, in Nanjing, China, Caremo, an innovative contract research organization (CRO) platform company, announced the successful completion of its Series A financing round, raising RMB 150 million (approximately USD 21 million). This round was led by Shapuaisi Pharma (SHA: 603168), a listed company, with follow-on investments from Jolmo Investment, Bondshine Capital, Huzhou Chunsheng, and other institutions. The proceeds will be utilized to accelerate the construction of Caremo’s R&D headquarters, enhance its integrated innovative pharmaceutical CRO service platform, and strengthen talent acquisition and team development.

Caremo is dedicated to providing one-stop, customizable pharmaceutical R&D solutions for global biotech and pharmaceutical enterprises. The company’s services span drug discovery, cell biology, pharmacology & pharmacodynamics, drug metabolism, non-clinical safety evaluation, formulation technologies, clinical research, as well as customized development and drug incubation investments. Caremo’s integrated, tailor-made solutions and end-to-end project management cover the full lifecycle from product ideation to commercialization, enabling efficient advancement of partners’ drug development pipelines.

To date, Caremo has assembled a 300+ member R&D team with extensive expertise in innovative drug development and evaluation. Over 10,000 square meters of facilities—including chemistry labs, P2 laboratories compliant with U.S. and Chinese regulatory standards, and hundreds of advanced instruments—are operational, while a 35,000-square-meter GLP-compliant R&D headquarters is currently under construction.

Dr. Zhang Xiaoqing, Chairman of Caremo, stated: "We are truly honored to receive recognition and support from numerous renowned investment partners! Under the influence of COVID-19, global attention and investment in the biopharmaceutical sector have reached unprecedented heights. With the rapid development of China's innovative pharmaceutical industry in recent years, the demand for one-stop pharmaceutical R&D services continues to grow, and the innovative CRO industry still has an extensive development period ahead. My team and I remain committed to establishing Caremo as an innovative, globally competitive one-stop CRO platform company rooted in China. We look forward to consistently sharing our progress with all friends who support Caremo, continuing to provide partners with high-quality customizable services, and enabling our R&D capabilities to accelerate the delivery of innovative therapies that benefit patients in China and worldwide."

· About Shapuaisi Pharma

Shapuaisi Pharma (Stock Code: 603168), established in 1978, is a comprehensive listed pharmaceutical enterprise specializing in drug R&D, production, and distribution. It successfully listed on the Shanghai Stock Exchange A-share Main Board on July 2, 2014. As a healthcare enterprise focused on medical services and pharmaceutical R&D-production-sales, the company specializes in ophthalmology and maternal-infant health fields.

Since its establishment, the company has consecutively passed the certification as a "National High-Tech Enterprise" four times and has been awarded honors including "National Torch Program Key High-Tech Enterprise," "Zhejiang Provincial Standard Innovation Enterprise," and "Zhejiang Top 100 Enterprises with Highest Investment Value." It has also received multiple accolades such as "Top 100 Chinese Pharmaceutical Industry Enterprises by Comprehensive Strength," "Outstanding Product Brand in Specialized Drug Categories of China's Chemical Pharmaceutical Industry," "OTC Excellent Product Brand in China's Chemical Pharmaceutical Industry," and "Social Responsibility Targeted Poverty Alleviation Award."

· About Jolmo Investment

Jolmo Investment Management Co., Ltd., a Vice President Unit of the Jiangsu Investment Fund Association, has been repeatedly recognized as one of the "Top 50 Venture Capital Institutions in China" by Zero2IPO and ChinaVenture. In 2019, it was honored as the "Jiangsu Provincial Leading Venture Capital Brand" and "Jiangsu Provincial Outstanding Venture Capital Team." Founded in 2004, the company has developed three core business segments through its operational platforms: private equity fund management, direct investment, and value-added services, with fund management being its primary focus.

Jolmo Investment currently manages funds exceeding RMB 10 billion and has established 40 private equity funds, including venture capital funds, merger & acquisition funds, and angel investment funds. The company focuses on strategic emerging industries such as new materials and intelligent manufacturing; new energy and eco-environment; new pharmaceuticals and healthcare; and semiconductors and innovative technologies. It has cultivated a specialized investment team with deep industry expertise, now comprising over 50 professionals. To date, Jolmo Investment has invested in nearly 200 projects, successfully facilitating 28 portfolio companies to list on stock exchanges, 11 exits via equity transfers, and 49 listings on the New Third Board.

· About Bondshine Capital

Bondshine Capital, established in 2014 through the mixed-ownership reform of Jiangsu High-Tech Investment Group, serves as a Vice President Unit of the Jiangsu Fund Industry Association and has been honored as the "Jiangsu Provincial Leading Venture Capital Brand" and "Jiangsu Provincial Outstanding Venture Capital Team." Bondshine Capital operates three private equity fund management platforms registered with the Asset Management Association of China (AMAC): Jiangsu Bondshine(P1001650), Coastal Capital(P1014378), and Bondshine Xingly(P1061949).

The company manages a diversified portfolio including angel funds, venture capital funds, industrial funds, and specialized sector funds, with cumulative assets under management exceeding RMB 10 billion. Bondshine Capital focuses on strategic emerging industries such as information technology, integrated circuits, healthcare, intelligent manufacturing, new energy, new materials, and sports culture, having invested in nearly 100 projects. It has successfully facilitated over 10 portfolio companies—including CIG Shanghai, Yuebooemt, Dingshengxincai, Liji Technology, SUMEC, Huarsheng, OF Technology, Guolian Securities, S-KING, Sunlord Electronics, NEUFTECH.